

Philippe Beutels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/16537/publications.pdf>

Version: 2024-02-01

258
papers

11,243
citations

46918

47
h-index

46693

89
g-index

283
all docs

283
docs citations

283
times ranked

11781
citing authors

#	ARTICLE	IF	CITATIONS
1	Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. PLoS Medicine, 2008, 5, e74.	3.9	2,355
2	Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiology, 2009, 4, 1303-1316.	1.0	280
3	Behavioural change models for infectious disease transmission: a systematic review (2010-2015). Journal of the Royal Society Interface, 2016, 13, 20160820.	1.5	252
4	Dynamic Epidemiological Models for Dengue Transmission: A Systematic Review of Structural Approaches. PLoS ONE, 2012, 7, e49085.	1.1	241
5	Precautionary Behavior in Response to Perceived Threat of Pandemic Influenza. Emerging Infectious Diseases, 2007, 13, 1307-1313.	2.0	209
6	Estimating the impact of school closure on social mixing behaviour and the transmission of close contact infections in eight European countries. BMC Infectious Diseases, 2009, 9, 187.	1.3	182
7	The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases. PLoS ONE, 2015, 10, e0133203.	1.1	165
8	A Systematic Review of Social Contact Surveys to Inform Transmission Models of Close-contact Infections. Epidemiology, 2019, 30, 723-736.	1.2	159
9	Indications for healthcare surge capacity in European countries facing an exponential increase in coronavirus disease (COVID-19) cases, March 2020. Eurosurveillance, 2020, 25, .	3.9	154
10	WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine, 2010, 28, 2356-2359.	1.7	145
11	Health Economics of Dengue: A Systematic Literature Review and Expert Panel's Assessment. American Journal of Tropical Medicine and Hygiene, 2011, 84, 473-488.	0.6	140
12	The possible macroeconomic impact on the UK of an influenza pandemic. Health Economics (United Kingdom) 2008, 28, 107-131.	0.8	131
13	The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands. European Journal of Health Economics, 2010, 11, 543-554.	1.4	127
14	Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infectious Diseases, The, 2007, 7, 289-296.	4.6	118
15	Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015). BMC Infectious Diseases, 2017, 17, 612.	1.3	118
16	Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models. Medical Decision Making, 2011, 31, 675-692.	1.2	115
17	Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiology and Infection, 2008, 136, 1059-1068.	1.0	109
18	Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Economics (United Kingdom), 2001, 10, 751-774.	0.8	107

#	ARTICLE	IF	CITATIONS
19	Seventy-five years of estimating the force of infection from current status data. <i>Epidemiology and Infection</i> , 2010, 138, 802-812.	1.0	100
20	Funding of drugs: do vaccines warrant a different approach?. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 727-733.	4.6	97
21	Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review. <i>PLoS ONE</i> , 2013, 8, e66485.	1.1	97
22	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. <i>Pharmacoeconomics</i> , 2016, 34, 227-244.	1.7	97
23	Mining social mixing patterns for infectious disease models based on a two-day population survey in Belgium. <i>BMC Infectious Diseases</i> , 2009, 9, 5.	1.3	95
24	CoMix: comparing mixing patterns in the Belgian population during and after lockdown. <i>Scientific Reports</i> , 2020, 10, 21885.	1.6	91
25	Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). <i>Vaccine</i> , 2007, 25, 2194-2212.	1.7	90
26	Modeling Infectious Disease Parameters Based on Serological and Social Contact Data. <i>Statistics in the Health Sciences</i> , 2012, , .	0.2	90
27	The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. <i>Vaccine</i> , 2009, 27, 6121-6128.	1.7	88
28	The impact of contact tracing and household bubbles on deconfinement strategies for COVID-19. <i>Nature Communications</i> , 2021, 12, 1524.	5.8	87
29	The economic impact of SARS in Beijing, China. <i>Tropical Medicine and International Health</i> , 2009, 14, 85-91.	1.0	86
30	A Nice Day for an Infection? Weather Conditions and Social Contact Patterns Relevant to Influenza Transmission. <i>PLoS ONE</i> , 2012, 7, e48695.	1.1	83
31	Estimating Infectious Disease Parameters from Data on Social Contacts and Serological Status. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2010, 59, 255-277.	0.5	82
32	Economic Evaluations of Varicella Vaccination Programmes. <i>Pharmacoeconomics</i> , 2003, 21, 13-38.	1.7	81
33	COVID-19 and retail: The catalyst for e-commerce in Belgium?. <i>Journal of Retailing and Consumer Services</i> , 2021, 62, 102645.	5.3	80
34	Economic Evaluation of Vaccination Programmes. <i>Pharmacoeconomics</i> , 2002, 20, 1-7.	1.7	77
35	Influenza epidemiology and immunization during pregnancy: Final report of a World Health Organization working group. <i>Vaccine</i> , 2017, 35, 5738-5750.	1.7	75
36	A look into the future of the COVID-19 pandemic in Europe: an expert consultation. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100185.	3.0	72

#	ARTICLE	IF	CITATIONS
37	Using empirical social contact data to model person to person infectious disease transmission: An illustration for varicella. <i>Mathematical Biosciences</i> , 2009, 218, 80-87.	0.9	68
38	The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness. <i>Health Affairs</i> , 2016, 35, 212-218.	2.5	67
39	Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2020, 222, S680-S687.	1.9	67
40	Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A Virus. <i>PLoS Computational Biology</i> , 2012, 8, e1002418.	1.5	66
41	Convincing or confusing?. <i>Vaccine</i> , 2007, 25, 1355-1367.	1.7	64
42	The cost-effectiveness of rotavirus vaccination in Australia. <i>Vaccine</i> , 2007, 25, 8851-8860.	1.7	61
43	Cost-Effectiveness of Rotavirus Vaccination: Exploring Caregiver(s) and "No Medical Care" Disease Impact in Belgium. <i>Medical Decision Making</i> , 2009, 29, 33-50.	1.2	59
44	The health and economic burden of chickenpox and herpes zoster in Belgium. <i>Epidemiology and Infection</i> , 2012, 140, 2096-2109.	1.0	59
45	SOCRATES: an online tool leveraging a social contact data sharing initiative to assess mitigation strategies for COVID-19. <i>BMC Research Notes</i> , 2020, 13, 293.	0.6	59
46	Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. <i>BMC Medicine</i> , 2020, 18, 82.	2.3	59
47	Modelling the early phase of the Belgian COVID-19 epidemic using a stochastic compartmental model and studying its implied future trajectories. <i>Epidemics</i> , 2021, 35, 100449.	1.5	55
48	Determinants of between-country differences in ambulatory antibiotic use and antibiotic resistance in Europe: a longitudinal observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 535-547.	1.3	54
49	Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2020, 222, S570-S576.	1.9	54
50	Prevaccination Distribution of Human Papillomavirus Types in Women Attending at Cervical Cancer Screening in Belgium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 321-330.	1.1	53
51	Reviewing the Cost Effectiveness of Rotavirus Vaccination. <i>Pharmacoeconomics</i> , 2009, 27, 281-297.	1.7	53
52	Methodological issues and new developments in the economic evaluation of vaccines. <i>Expert Review of Vaccines</i> , 2003, 2, 649-660.	2.0	51
53	Influenza-Like-Illness and Clinically Diagnosed Flu: Disease Burden, Costs and Quality of Life for Patients Seeking Ambulatory Care or No Professional Care at All. <i>PLoS ONE</i> , 2014, 9, e102634.	1.1	51
54	Public Preferences for Prioritizing Preventive and Curative Health Care Interventions: A Discrete Choice Experiment. <i>Value in Health</i> , 2015, 18, 224-233.	0.1	51

#	ARTICLE	IF	CITATIONS
55	Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. <i>Health Economics (United Kingdom)</i> , 2008, 17, 1317-1322.	0.8	50
56	Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium. <i>Epidemiology and Infection</i> , 2011, 139, 494-504.	1.0	48
57	Appropriate international measures for outpatient antibiotic prescribing and consumption: recommendations from a national data comparison of different measures. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 529-534.	1.3	47
58	Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non-responders. <i>Vaccine</i> , 2018, 36, 6282-6289.	1.7	47
59	A Systematic Review of Clinical Practice Guidelines for the Diagnosis and Management of Bronchiolitis. <i>Journal of Infectious Diseases</i> , 2020, 222, S672-S679.	1.9	47
60	Estimating the Incidence of Symptomatic Rotavirus Infections: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2009, 4, e6060.	1.1	46
61	Costing Infectious Disease Outbreaks for Economic Evaluation. <i>Pharmacoeconomics</i> , 2009, 27, 379-389.	1.7	46
62	Estimating dynamic transmission model parameters for seasonal influenza by fitting to age and season-specific influenza-like illness incidence. <i>Epidemics</i> , 2015, 13, 1-9.	1.5	46
63	Individual decisions to vaccinate one's child or oneself: A discrete choice experiment rejecting free-riding motives. <i>Social Science and Medicine</i> , 2018, 207, 106-116.	1.8	46
64	SOCRATES-CoMix: a platform for timely and open-source contact mixing data during and in between COVID-19 surges and interventions in over 20 European countries. <i>BMC Medicine</i> , 2021, 19, 254.	2.3	45
65	The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). <i>European Journal of Pediatrics</i> , 2002, 161, 588-593.	1.3	44
66	Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. <i>Eurosurveillance</i> , 2016, 21, .	3.9	44
67	Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006-2014). <i>Vaccine</i> , 2015, 33, 1633-1658.	1.7	42
68	A simple periodic-forced model for dengue fitted to incidence data in Singapore. <i>Mathematical Biosciences</i> , 2013, 244, 22-28.	0.9	40
69	An update to "The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe". <i>Vaccine</i> , 2010, 28, 7457-7459.	1.7	39
70	Guidelines for multi-model comparisons of the impact of infectious disease interventions. <i>BMC Medicine</i> , 2019, 17, 163.	2.3	39
71	Valuing Prevention Through Economic Evaluation. <i>Pharmacoeconomics</i> , 2004, 22, 1171-1179.	1.7	38
72	An economic evaluation of varicella vaccination in Italian adolescents. <i>Vaccine</i> , 2004, 22, 3546-3562.	1.7	38

#	ARTICLE	IF	CITATIONS
73	Childhood varicella-zoster virus vaccination in Belgium: Cost-effective only in the long run or without exogenous boosting?. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 812-822.	1.4	38
74	Estimating Time of Infection Using Prior Serological and Individual Information Can Greatly Improve Incidence Estimation of Human and Wildlife Infections. <i>PLoS Computational Biology</i> , 2016, 12, e1004882.	1.5	38
75	The Role of Economic Evaluation in Vaccine Decision Making. <i>Pharmacoeconomics</i> , 2005, 23, 855-874.	1.7	36
76	Towards a European strategy to address the COVID-19 pandemic. <i>Lancet, The</i> , 2021, 398, 838-839.	6.3	36
77	Economic Aspects of Pneumococcal Pneumonia. <i>Pharmacoeconomics</i> , 2004, 22, 719-740.	1.7	35
78	Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 834-840.	1.4	35
79	A data-driven metapopulation model for the Belgian COVID-19 epidemic: assessing the impact of lockdown and exit strategies. <i>BMC Infectious Diseases</i> , 2021, 21, 503.	1.3	35
80	Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 286-295.	4.6	34
81	Exploring the Impact of Exposure to Primary Varicella in Children on Varicella-Zoster Virus Immunity of Parents. <i>Viral Immunology</i> , 2011, 24, 151-157.	0.6	32
82	The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 39.	1.2	32
83	Estimating the effective reproduction number for pandemic influenza from notification data made publicly available in real time: A multi-country analysis for influenza A/H1N1v 2009. <i>Vaccine</i> , 2011, 29, 896-904.	1.7	31
84	Household members do not contact each other at random: implications for infectious disease modelling. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2018, 285, 20182201.	1.2	31
85	Like mother, like daughter? Mother's history of cervical cancer screening and daughter's Human Papillomavirus vaccine uptake in Flanders (Belgium). <i>Vaccine</i> , 2011, 29, 8390-8396.	1.7	30
86	Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (Julyâ€“December 2020). <i>Vaccine</i> , 2022, 40, 151-161.	1.7	30
87	Model structure analysis to estimate basic immunological processes and maternal risk for parvovirus B19. <i>Biostatistics</i> , 2011, 12, 283-302.	0.9	28
88	Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox. <i>Scientific Reports</i> , 2017, 7, 1077.	1.6	28
89	Drivers of vaccine decision-making in South Africa: A discrete choice experiment. <i>Vaccine</i> , 2019, 37, 2079-2089.	1.7	28
90	Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. <i>Eurosurveillance</i> , 2018, 23, .	3.9	28

#	ARTICLE	IF	CITATIONS
91	Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster. <i>ELife</i> , 2015, 4, .	2.8	28
92	On Discounting of Health Gains from Human Papillomavirus Vaccination: Effects of Different Approaches. <i>Value in Health</i> , 2012, 15, 562-567.	0.1	27
93	Kicking against the pricks: vaccine sceptics have a different social orientation. <i>European Journal of Public Health</i> , 2014, 24, 310-314.	0.1	27
94	The social contact hypothesis under the assumption of endemic equilibrium: Elucidating the transmission potential of VZV in Europe. <i>Epidemics</i> , 2015, 11, 14-23.	1.5	27
95	The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium. <i>Vaccine</i> , 2016, 34, 2106-2112.	1.7	27
96	Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. <i>Vaccine</i> , 2004, 22, 3312-3322.	1.7	26
97	The health and economic burden of rotavirus disease in Belgium. <i>European Journal of Pediatrics</i> , 2008, 167, 1409-1419.	1.3	26
98	Influence of Frequent Infectious Exposures on General and Varicella-Zoster Virus-Specific Immune Responses in Pediatricians. <i>Vaccine Journal</i> , 2014, 21, 417-426.	3.2	26
99	Preferential differences in vaccination decision-making for oneself or one's child in The Netherlands: a discrete choice experiment. <i>BMC Public Health</i> , 2020, 20, 828.	1.2	26
100	Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100221.	3.0	26
101	Health-related quality of life in patients with melanoma expressed as utilities and disability weights. <i>British Journal of Dermatology</i> , 2014, 171, 1443-1450.	1.4	25
102	Selective Use of Sequential Digital Dermoscopy Imaging Allows a Cost Reduction in the Melanoma Detection Process: A Belgian Study of Patients with a Single or a Small Number of Atypical Nevi. <i>PLoS ONE</i> , 2014, 9, e109339.	1.1	25
103	Assessing the risk of measles resurgence in a highly vaccinated population: Belgium anno 2013. <i>Eurosurveillance</i> , 2015, 20, .	3.9	25
104	Economic evaluations applied to HB vaccination: general observations. <i>Vaccine</i> , 1998, 16, S84-S92.	1.7	24
105	Application of mixed-effects models to study the country-specific outpatient antibiotic use in Europe: a tutorial on longitudinal data analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, vi79-vi87.	1.3	24
106	Patient and prescriber determinants for the choice between amoxicillin and broader-spectrum antibiotics: a nationwide prescription-level analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2383-2392.	1.3	24
107	The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 141-151.	0.7	24
108	Active Learning to Understand Infectious Disease Models and Improve Policy Making. <i>PLoS Computational Biology</i> , 2014, 10, e1003563.	1.5	24

#	ARTICLE	IF	CITATIONS
109	Serology indicates cytomegalovirus infection is associated with varicella-zoster virus reactivation. <i>Journal of Medical Virology</i> , 2014, 86, 812-819.	2.5	24
110	Consumer Choice Between Common Generic and Brand Medicines in a Country with a Small Generic Market. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 288-296.	0.5	24
111	Estimating the population prevalence and force of infection directly from antibody titres. <i>Statistical Modelling</i> , 2012, 12, 441-462.	0.5	23
112	Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. <i>Vaccine</i> , 2012, 30, 675-684.	1.7	23
113	Assessing Mumps Outbreak Risk in Highly Vaccinated Populations Using Spatial Seroprevalence Data. <i>American Journal of Epidemiology</i> , 2014, 179, 1006-1017.	1.6	23
114	Environmental triggers of acute myocardial infarction: results of a nationwide multiple-factorial population study. <i>Acta Cardiologica</i> , 2015, 70, 693-701.	0.3	23
115	Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. <i>Vaccine</i> , 2017, 35, 345-352.	1.7	23
116	Cost-effectiveness of contemporary vascular closure devices for the prevention of vascular complications after percutaneous coronary interventions in an all-comers PCI population. <i>EuroIntervention</i> , 2014, 10, 191-197.	1.4	23
117	Estimating the age-specific duration of herpes zoster vaccine protection: A matter of model choice?. <i>Vaccine</i> , 2012, 30, 2795-2800.	1.7	22
118	Belgian population norms for the EQ-5D-5L, 2018. <i>Quality of Life Research</i> , 2022, 31, 527-537.	1.5	22
119	A brief history of economic evaluation for human papillomavirus vaccination policy. <i>Sexual Health</i> , 2010, 7, 352.	0.4	21
120	Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective. <i>Value in Health</i> , 2021, 24, 105-111.	0.1	21
121	How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. <i>Eurosurveillance</i> , 2020, 25, .	3.9	21
122	Economic Evaluations of Childhood Influenza Vaccination. <i>Pharmacoeconomics</i> , 2012, 30, 647-660.	1.7	20
123	Varicella-Zoster Virus-Derived Major Histocompatibility Complex Class I-Restricted Peptide Affinity Is a Determining Factor in the HLA Risk Profile for the Development of Postherpetic Neuralgia. <i>Journal of Virology</i> , 2015, 89, 962-969.	1.5	20
124	Melanoma burden by melanoma stage: Assessment through a disease transition model. <i>European Journal of Cancer</i> , 2016, 53, 33-41.	1.3	20
125	Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary Care (ALIC ⁴ E): the ALIC ⁴ E protocol. <i>BMJ Open</i> , 2018, 8, e021032.	0.8	20
126	Close contact infection dynamics over time: insights from a second large-scale social contact survey in Flanders, Belgium, in 2010-2011. <i>BMC Infectious Diseases</i> , 2021, 21, 274.	1.3	20

#	ARTICLE	IF	CITATIONS
127	The influence of risk perceptions on close contact frequency during the SARS-CoV-2 pandemic. <i>Scientific Reports</i> , 2022, 12, 5192.	1.6	20
128	Contact patterns and their implied basic reproductive numbers: an illustration for varicella-zoster virus. <i>Epidemiology and Infection</i> , 2009, 137, 48-57.	1.0	19
129	Vaccination Policy and Ethical Challenges Posed by Herd Immunity, Suboptimal Uptake and Subgroup Targeting. <i>Public Health Ethics</i> , 2011, 4, 280-291.	0.4	19
130	Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability. <i>Pharmacoeconomics</i> , 2013, 31, 693-702.	1.7	19
131	Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1218-1229.	1.4	19
132	Memory CD4+ T cell receptor repertoire data mining as a tool for identifying cytomegalovirus serostatus. <i>Genes and Immunity</i> , 2019, 20, 255-260.	2.2	19
133	Respiratory syncytial virus and influenza virus infection in adult primary care patients: Association of age with prevalence, diagnostic features and illness course. <i>International Journal of Infectious Diseases</i> , 2020, 95, 384-390.	1.5	19
134	Respiratory Syncytial Virus-associated Hospital Admissions and Bed Days in Children ≤ 5 Years of Age in 7 European Countries. <i>Journal of Infectious Diseases</i> , 2022, 226, S22-S28.	1.9	19
135	Seroprevalence of IgG antibodies against SARS-CoV-2 in a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020. <i>Eurosurveillance</i> , 2022, 27, .	3.9	19
136	Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. <i>BMC Medicine</i> , 2011, 9, 53.	2.3	18
137	Modelling multisera data: The estimation of new joint and conditional epidemiological parameters. <i>Statistics in Medicine</i> , 2008, 27, 2651-2664.	0.8	17
138	Cost-effectiveness of hepatitis A vaccination in Indonesia. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2342-2349.	1.4	17
139	Optimizing agent-based transmission models for infectious diseases. <i>BMC Bioinformatics</i> , 2015, 16, 183.	1.2	17
140	A trial like ALICE: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness?. <i>ERJ Open Research</i> , 2018, 4, 00046-2018.	1.1	17
141	Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe. <i>Journal of Infectious Diseases</i> , 2020, 222, S606-S612.	1.9	17
142	Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination. <i>Journal of Infectious Diseases</i> , 2020, 222, S688-S694.	1.9	17
143	Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT study. <i>BMC Public Health</i> , 2022, 22, .	1.2	17
144	Imputing QALYs from Single Time Point Health State Descriptions on the EQ-5D and the SF-6D: A Comparison of Methods for Hepatitis A Patients. <i>Value in Health</i> , 2011, 14, 282-290.	0.1	16

#	ARTICLE	IF	CITATIONS
145	Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium. <i>Vaccine</i> , 2014, 32, 6075-6083.	1.7	16
146	Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. <i>Vaccine</i> , 2014, 32, 759-765.	1.7	16
147	The Cost of Arbovirus Disease Prevention in Europe: Area-Wide Integrated Control of Tiger Mosquito, <i>Aedes albopictus</i> , in Emilia-Romagna, Northern Italy. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 444.	1.2	16
148	Inferring age-specific differences in susceptibility to and infectiousness upon SARS-CoV-2 infection based on Belgian social contact data. <i>PLoS Computational Biology</i> , 2022, 18, e1009965.	1.5	16
149	Economic Evaluation of Vaccination. <i>Pharmacoeconomics</i> , 1996, 9, 8-15.	1.7	15
150	Modelling forces of infection by using monotone local polynomials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2003, 52, 469-485.	0.5	15
151	The Sexual Ethics of HPV Vaccination for Boys. <i>HEC Forum</i> , 2014, 26, 27-42.	0.6	15
152	Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical. <i>Vaccine</i> , 2016, 34, 320-327.	1.7	15
153	Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children. <i>Journal of Infectious Diseases</i> , 2022, 226, S95-S101.	1.9	15
154	Varicella-zoster virus vaccination under the exogenous boosting hypothesis: Two ethical perspectives. <i>Vaccine</i> , 2014, 32, 7175-7178.	1.7	14
155	Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. <i>Vaccine</i> , 2018, 36, 6307-6313.	1.7	14
156	Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country. <i>Contemporary Clinical Trials</i> , 2020, 99, 106189.	0.8	14
157	Can COVID-19 symptoms as reported in a large-scale online survey be used to optimise spatial predictions of COVID-19 incidence risk in Belgium?. <i>Spatial and Spatio-temporal Epidemiology</i> , 2020, 35, 100379.	0.9	14
158	In-depth analysis of pneumococcal serotypes in Belgian children (2015-2018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease. <i>Vaccine</i> , 2021, 39, 372-379.	1.7	14
159	Introduction of Human Papillomavirus Vaccination in Belgium, Luxembourg and the Netherlands. <i>Gynecologic and Obstetric Investigation</i> , 2010, 70, 224-232.	0.7	13
160	Animal Ownership and Touching Enrich the Context of Social Contacts Relevant to the Spread of Human Infectious Diseases. <i>PLoS ONE</i> , 2015, 10, e0133461.	1.1	13
161	Herpes zoster is associated with herpes simplex and other infections in under 60 year-olds. <i>Journal of Infection</i> , 2015, 70, 171-177.	1.7	13
162	The impact of non-financial and financial encouragements on participation in non school-based human papillomavirus vaccination: a retrospective cohort study. <i>European Journal of Health Economics</i> , 2016, 17, 305-315.	1.4	13

#	ARTICLE	IF	CITATIONS
163	Workplace influenza vaccination to reduce employee absenteeism: An economic analysis from the employersâ€™ perspective. <i>Vaccine</i> , 2021, 39, 2005-2015.	1.7	13
164	Economic evaluations of adult pneumococcal vaccination strategies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001, 1, 47-58.	0.7	12
165	The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT. <i>Journal of Immunological Methods</i> , 2010, 357, 51-54.	0.6	12
166	Cost-effectiveness of hepatitis A vaccination for adults in Belgium. <i>Vaccine</i> , 2012, 30, 6070-6080.	1.7	12
167	Public preferences over efficiency, equity and autonomy in vaccination policy: An empirical study. <i>Social Science and Medicine</i> , 2013, 77, 84-89.	1.8	12
168	Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. <i>Vaccine</i> , 2017, 35, 4307-4314.	1.7	12
169	The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models. <i>Vaccine</i> , 2020, 38, 5139-5147.	1.7	12
170	Estimating the impact of vaccination using ageâ€“time-dependent incidence rates of hepatitis B. <i>Epidemiology and Infection</i> , 2008, 136, 341-351.	1.0	11
171	Common attitudes about concomitant vaccine injections for infants and adolescents in Flanders, Belgium. <i>Vaccine</i> , 2009, 27, 1964-1969.	1.7	11
172	Community-acquired pneumonia (CAP) hospitalizations and deaths: is there a role for quality improvement through inter-hospital comparisons?. <i>International Journal for Quality in Health Care</i> , 2016, 28, 22-32.	0.9	11
173	Structural differences in mixing behavior informing the role of asymptomatic infection and testing symptom heritability. <i>Mathematical Biosciences</i> , 2017, 285, 43-54.	0.9	11
174	Effectiveness of a Malaria Surveillance Strategy Based on Active Case Detection during High Transmission Season in the Peruvian Amazon. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2670.	1.2	11
175	Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, S666-S671.	1.9	11
176	World Health Organization Influenza-Like Illness Underestimates the Burden of Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 226, S71-S78.	1.9	11
177	Costâ€“effectiveness of screening for active cases of tuberculosis in Flanders, Belgium. <i>Bulletin of the World Health Organization</i> , 2017, 95, 27-35.	1.5	11
178	Preexisting memory CD4 T cells in naÃ“ve individuals confer robust immunity upon hepatitis B vaccination. <i>ELife</i> , 2022, 11, .	2.8	11
179	Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium. <i>Leukemia Research</i> , 2016, 46, 26-29.	0.4	10
180	Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. <i>European Journal of Cancer</i> , 2016, 67, 38-45.	1.3	10

#	ARTICLE	IF	CITATIONS
181	The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia. <i>Vaccine</i> , 2018, 36, 1265-1271.	1.7	10
182	Clustering of susceptible individuals within households can drive measles outbreaks: an individual-based model exploration. <i>Scientific Reports</i> , 2020, 10, 19645.	1.6	10
183	Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections. <i>Journal of Infectious Diseases</i> , 2020, 222, S584-S591.	1.9	10
184	Economic costs analysis of uncomplicated malaria case management in the Peruvian Amazon. <i>Malaria Journal</i> , 2020, 19, 161.	0.8	10
185	Care-seeking behaviour and socio-economic burden associated with uncomplicated malaria in the Democratic Republic of Congo. <i>Malaria Journal</i> , 2021, 20, 260.	0.8	10
186	Cost Effectiveness of Alternative Hepatitis A Immunisation Strategies. <i>Pharmacoeconomics</i> , 1995, 8, 5-8.	1.7	9
187	An Economic Evaluation of Hepatitis A Vaccination in Dutch Military Personnel. <i>Military Medicine</i> , 1998, 163, 564-567.	0.4	9
188	Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: costeffectiveness analyses and implications for The Netherlands. <i>Expert Review of Vaccines</i> , 2003, 2, 477-482.	2.0	9
189	Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience. <i>Transplant Infectious Disease</i> , 2013, 15, 70-78.	0.7	9
190	Data mining for longitudinal data under multicollinearity and time dependence using penalized generalized estimating equations. <i>Computational Statistics and Data Analysis</i> , 2014, 71, 667-680.	0.7	9
191	Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation. <i>Epidemiology and Infection</i> , 2014, 142, 251-261.	1.0	9
192	Cytomegalovirus seropositivity is associated with herpes zoster. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1394-1399.	1.4	9
193	Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges. <i>Pharmacoeconomics</i> , 2016, 34, 723-731.	1.7	9
194	Sponsorship Bias in Base-Case Values and Uncertainty Bounds of Health Economic Evaluations? A Systematic Review of Herpes Zoster Vaccination. <i>Medical Decision Making</i> , 2018, 38, 730-745.	1.2	9
195	Altered CD4+ T cell immunity in nurses occupationally exposed to viral pathogens. <i>Clinical and Experimental Immunology</i> , 2018, 194, 192-204.	1.1	9
196	An ODE-based mixed modelling approach for B- and T-cell dynamics induced by Varicella-Zoster Virus vaccines in adults shows higher T-cell proliferation with Shingrix than with Varilrix. <i>Vaccine</i> , 2019, 37, 2537-2553.	1.7	9
197	Recent quantitative research on determinants of health in high income countries: A scoping review. <i>PLoS ONE</i> , 2020, 15, e0239031.	1.1	9
198	Performance Assessment of a Rapid Molecular Respiratory Syncytial Virus Point-of-Care Test: A Prospective Community Study in Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 226, S63-S70.	1.9	9

#	ARTICLE	IF	CITATIONS
199	CAREGIVERSâ€™ WILLINGNESS TO PAY TO REDUCE THE NUMBER OF VACCINE INJECTIONS IN INFANTS. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 61-63.	1.1	8
200	Inferring rubella outbreak risk from seroprevalence data in Belgium. <i>Vaccine</i> , 2016, 34, 6187-6192.	1.7	8
201	Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity. <i>Immunogenetics</i> , 2018, 70, 363-372.	1.2	8
202	No Such Thing as a Free-Rider? Understanding Drivers of Childhood and Adult Vaccination through a Multicountry Discrete Choice Experiment. <i>Vaccines</i> , 2021, 9, 264.	2.1	8
203	Quality-of-life: a many-splendored thing? Belgian population norms and 34 potential determinants explored by beta regression. <i>Quality of Life Research</i> , 2017, 26, 2011-2023.	1.5	7
204	The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in Belgium. <i>Archives of Public Health</i> , 2017, 75, 42.	1.0	7
205	Low Sensitivity of BinaxNOW RSV in Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, S640-S647.	1.9	6
206	A Computationally Efficient Method for Probabilistic Parameter Threshold Analysis for Health Economic Evaluations. <i>Medical Decision Making</i> , 2020, 40, 669-679.	1.2	6
207	Unveiling the Risk Period for Death After Respiratory Syncytial Virus Illness in Young Children Using a Self-Controlled Case Series Design. <i>Journal of Infectious Diseases</i> , 2020, 222, S634-S639.	1.9	6
208	Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC4E Trial. <i>Clinical Drug Investigation</i> , 2021, 41, 685-699.	1.1	6
209	Comments on the Prosser et al Approach to Value Disease Reduction in Children. <i>Pediatrics</i> , 2004, 114, 1375-1375.	1.0	5
210	Modelling distortions in seroprevalence data using change-point fractional polynomials. <i>Statistical Modelling</i> , 2010, 10, 159-175.	0.5	5
211	Estimating vaccination coverage for the trivalent measlesâ€“mumpsâ€“rubella vaccine from trivariate serological data. <i>Statistics in Medicine</i> , 2012, 31, 1432-1449.	0.8	5
212	Adaptive change-point mixed models applied to data on outpatient tetracycline use in Europe. <i>Statistical Modelling</i> , 2013, 13, 253-274.	0.5	5
213	The health and economic impact of acute gastroenteritis in Belgium, 2010â€“2014. <i>Epidemiology and Infection</i> , 2019, 147, e146.	1.0	5
214	<i>Streptococcus pneumoniae</i> Serotypes Carried by Young Children and Their Association With Acute Otitis Media During the Period 2016â€“2019. <i>Frontiers in Pediatrics</i> , 2021, 9, 664083.	0.9	5
215	Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice. <i>Medical Decision Making</i> , 2022, 42, 421-435.	1.2	5
216	Hepatitis A vaccine for secondary hepatitis A infection. <i>Lancet</i> , The, 1999, 354, 340-341.	6.3	4

#	ARTICLE	IF	CITATIONS
217	Estimation of the Force of Infection from Current Status Data Using Generalized Linear Mixed Models. <i>Journal of Applied Statistics</i> , 2007, 34, 923-939.	0.6	4
218	Zoster in Monasteries: Some Clarification Needed. <i>Clinical Infectious Diseases</i> , 2012, 54, 305-306.	2.9	4
219	Evolutions in Both Co-Payment and Generic Market Share for Common Medication in the Belgian Reference Pricing System. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 543-552.	1.0	4
220	Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. <i>Vaccine</i> , 2018, 36, 2057-2060.	1.7	4
221	Value Frameworks for Vaccines: Which Dimensions Are Most Relevant?. <i>Vaccines</i> , 2020, 8, 628.	2.1	4
222	Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK. <i>PLoS ONE</i> , 2021, 16, e0252836.	1.1	4
223	Cost-Effectiveness of Socioeconomic Support as Part of HIV Care for the Poor in an Urban Community-Based Antiretroviral Program in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, e76-e83.	0.9	3
224	Medicine price awareness in chronic patients in Belgium. <i>Health Policy</i> , 2015, 119, 217-223.	1.4	3
225	Priority-Setting and Personality: Effects of Dispositional Optimism on Preferences for Allocating Healthcare Resources. <i>Social Justice Research</i> , 2019, 32, 186-207.	0.6	3
226	Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness. <i>Value in Health</i> , 2022, 25, 178-184.	0.1	3
227	Cost Analysis of Immunotherapy Using Dendritic Cells for Acute Myeloid Leukemia Patients. <i>Blood</i> , 2014, 124, 1322-1322.	0.6	3
228	Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine. <i>Pharmacoeconomics</i> , 2022, 40, 461-476.	1.7	3
229	The burden of isolation to the individual: a comparison between isolation for COVID-19 and for other influenza-like illnesses in Japan. <i>Epidemiology and Infection</i> , 2022, 150, .	1.0	3
230	Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors?? Reply. <i>Pharmacoeconomics</i> , 2004, 22, 136-138.	1.7	2
231	Funding of drugs: do vaccines warrant a different approach? â€œ Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 270-271.	4.6	2
232	Response to comment on article by Jit et al. â€œThe cost effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europeâ€•. <i>Vaccine</i> , 2011, 29, 3732-3733.	1.7	2
233	What counts in cytometric analysis to document vaccine immunogenicity?. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 499-500.	1.4	2
234	â€˜Egocentricâ€™ Vaccination: The Authors Reply. <i>Health Affairs</i> , 2016, 35, 937-937.	2.5	2

#	ARTICLE	IF	CITATIONS
235	UK experience of herpes zoster vaccination can inform varicella zoster virus policies. <i>Lancet Public Health, The</i> , 2018, 3, e57-e58.	4.7	2
236	Aggregate Wellbeing as Foundation to Discourage Childhood Chickenpox Vaccination. <i>American Journal of Bioethics</i> , 2020, 20, 58-60.	0.5	2
237	Sampling Site Matters When Counting Lymphocyte Subpopulations. <i>PLoS ONE</i> , 2012, 7, e41405.	1.1	2
238	Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials. <i>Journal of Clinical Epidemiology</i> , 2022, 147, 11-20.	2.4	2
239	Social preferences for adopting new vaccines in the national immunization program: A discrete choice experiment. <i>Social Science and Medicine</i> , 2022, 303, 114991.	1.8	2
240	Detection of SARS-CoV-2 in young children attending day-care centres in Belgium, May 2020 to February 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	2
241	A spatial model to jointly analyze self-reported survey data of COVID-19 symptoms and official COVID-19 incidence data. <i>Biometrical Journal</i> , 2023, 65, .	0.6	2
242	Effectiveness of seven-valent pneumococcal conjugate vaccine. <i>Lancet, The</i> , 2007, 369, 460.	6.3	1
243	Links Between Herpes Zoster Incidence and Childhood Varicella Vaccination. <i>Annals of Internal Medicine</i> , 2014, 160, 582.	2.0	1
244	The seroprevalence of cytomegalovirus infection in Belgium anno 2002 and 2006: a comparative analysis with hepatitis A virus seroprevalence. <i>Epidemiology and Infection</i> , 2019, 147, e154.	1.0	1
245	Transcriptomic profiling of different responder types in adults after a Priorix® vaccination. <i>Vaccine</i> , 2020, 38, 3218-3226.	1.7	1
246	Economic evaluation of childhood vaccines. , 2009, , 211-224.		1
247	Revealing age-specific past and future unrelated costs of pneumococcal infections by flexible generalized estimating equations. <i>Journal of Applied Statistics</i> , 2011, 38, 1533-1547.	0.6	0
248	Using an adaptive trial design for an infectious disease in primary care - challenges in the design and set-up stages. <i>Trials</i> , 2015, 16, .	0.7	0
249	Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. <i>Vaccine</i> , 2019, 37, 7534.	1.7	0
250	Ceci n'est pas un lit. Base capacity healthcare matters in a pandemic. <i>Lancet Regional Health - Europe, The</i> , 2021, 2, 100033.	3.0	0
251	Recent quantitative research on determinants of health in high income countries: A scoping review. , 2020, 15, e0239031.		0
252	Recent quantitative research on determinants of health in high income countries: A scoping review. , 2020, 15, e0239031.		0

#	ARTICLE	IF	CITATIONS
253	Recent quantitative research on determinants of health in high income countries: A scoping review. , 2020, 15, e0239031.		0
254	Recent quantitative research on determinants of health in high income countries: A scoping review. , 2020, 15, e0239031.		0
255	Recent quantitative research on determinants of health in high income countries: A scoping review. , 2020, 15, e0239031.		0
256	Recent quantitative research on determinants of health in high income countries: A scoping review. , 2020, 15, e0239031.		0
257	Recent quantitative research on determinants of health in high income countries: A scoping review. , 2020, 15, e0239031.		0
258	Recent quantitative research on determinants of health in high income countries: A scoping review. , 2020, 15, e0239031.		0